A. Chakravartty

572 total citations · 1 hit paper
10 papers, 287 citations indexed

About

A. Chakravartty is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, A. Chakravartty has authored 10 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 1 paper in Epidemiology. Recurrent topics in A. Chakravartty's work include Advanced Breast Cancer Therapies (9 papers), Lung Cancer Research Studies (4 papers) and HER2/EGFR in Cancer Research (3 papers). A. Chakravartty is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Lung Cancer Research Studies (4 papers) and HER2/EGFR in Cancer Research (3 papers). A. Chakravartty collaborates with scholars based in United States, Germany and Italy. A. Chakravartty's co-authors include Gabe S. Sonke, Katarína Petráková, Guy Jérusalem, Juan Pablo Zarate, Dennis J. Slamon, Luis de la Cruz‐Merino, Stephen Chia, Michelino De Laurentiis, Patrick Neven and Giulia Bianchi and has published in prestigious journals such as Cancer Research, Annals of Oncology and European Journal of Cancer.

In The Last Decade

A. Chakravartty

9 papers receiving 284 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 161 citations Dennis J. Slamon, Patrick Neven et al. Annals of Oncology profile →

Peers

Countries citing papers authored by A. Chakravartty

Since Specialization

Citations

This map shows the geographic impact of A. Chakravartty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Chakravartty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Chakravartty more than expected).

Fields of papers citing papers by A. Chakravartty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Chakravartty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Chakravartty. The network helps show where A. Chakravartty may publish in the future.

Co-authorship network of co-authors of A. Chakravartty

This figure shows the co-authorship network connecting the top 25 collaborators of A. Chakravartty. A scholar is included among the top collaborators of A. Chakravartty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Chakravartty. A. Chakravartty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials 2024 ·Annals of Oncology ·Fabrice André, Nadia Solovieff, Fei Su, Aditya Bardia, Patrick Neven, Yoon Sim Yap, Debu Tripathy, Yen‐Shen Lu, DJ Slamon, Stephen Chia, Molishree Joshi, A. Chakravartty, Aida Lteif, T Taran, Carlos L. Arteaga	5
2	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant 2023 ·Breast Cancer Research ·Patrick Neven, PA Fasching, Stephen Chia, Guy Jérusalem, Michelino De Laurentiis, Seock‐Ah Im, Katarína Petráková, Giulia Bianchi, (unknown), Arnd Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Juan Pablo Zarate, (unknown), A. Chakravartty, (unknown), Dennis J. Slamon	33
3	LBA23 Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC) 2023 ·Annals of Oncology ·Aditya Bardia, Gabriel N. Hortobágyi, Oleg Lipatov, Nicholas P. McAndrew, Aleksandra Łacko, Joohyuk Sohn, L. Hart, John Crown, S-A Im, Nadia Harbeck, J. O’Shaughnessy, Binghe Xu, Carlos H. Barrios, R Moroose, (unknown), Rodrigo Fresco, Farhat Ghaznawi, Simon Waters, A. Chakravartty, Dennis J. Slamon	0
4	LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL) 2022 ·Annals of Oncology ·(unknown), Peter A. Fasching, (unknown), Guy Jérusalem, Michelino De Laurentiis, Sun Im, Katarína Petráková, Giulia Bianchi, M. Martín Jiménez, (unknown), Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, (unknown), (unknown), A. Chakravartty, (unknown), Dennis J. Slamon	7
5	LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) 2021 ·Annals of Oncology ·G. N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, L. Hart, M. Campone, Katarína Petráková, Eric P. Winer, W Janni, Pierfranco Conté, David Cameron, Fabrice André, CL Arteaga, Juan Pablo Zarate, A. Chakravartty, Tanya Taran, Fabienne Le Gac, Patrizia Serra, Joyce O’Shaughnessy	41
6	Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival breakdown → 2021 ·Annals of Oncology ·Dennis J. Slamon, Patrick Neven, Stephen Chia, Guy Jérusalem, Michelino De Laurentiis, Sin‐Hyeog Im, Katarína Petráková, Giulia Bianchi, Miguel Martín, Arnd Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Yan Ji, (unknown), (unknown), A. Chakravartty, Juan Pablo Zarate, T Taran, Peter A. Fasching	161
7	93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) 2021 ·Annals of Oncology ·Yen‐Shen Lu, Nagi S. El Saghir, Sara A. Hurvitz, Debu Tripathy, Fátima Cardoso, Marco Colleoni, Saúl Campos-Gómez, Fábio Franke, (unknown), (unknown), (unknown), Juan Pablo Zarate, A. Chakravartty, S-A. Im	1
8	Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) 2019 ·Annals of Oncology ·Dennis J. Slamon, Patrick Neven, Stephen Chia, PA Fasching, Michelino De Laurentiis, S.-A. Im, Katarína Petráková, Giulia Bianchi, Francisco J. Esteva, Marta Gil-Martín, (unknown), Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Xavier Pivot, (unknown), (unknown), A. Chakravartty, Karen Rodriguez-Lorenc, Guy Jérusalem	37
9	Abstract OT3-05-06: EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), intermediate-risk, early breast cancer (EBC) 2018 ·Cancer Research ·J. O’Shaughnessy, Emilio Alba, Aditya Bardia, Susan Dent, Véronique Dièras, Gabriel N. Hortobágyi, S-A Im, Filippo Montemurro, Michael Untch, DA Yardley, A. Chakravartty, Caroline Germa, Michelle C. Miller, Dennis J. Slamon	1
10	2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC) 2015 ·European Journal of Cancer ·K.N. Chi, Daniel Castellano, Johann S. de Bono, Gwénaëlle Gravis, Luc Dirix, J-P. Machiels, (unknown), B. Mellado González, C. Massard, Lucia Trandafir, (unknown), Dénes Csonka, A. Chakravartty, Karim Fizazi	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact